Program
piflufolastat
Also written as “piflufolastat (18F)”, “piflufolastat F 18” and “Piflufolastat F 18 Intravenous Solution [PYLARIFY]”.
Its studies are mostly in Prostatic Neoplasms · Carcinoma, Renal Cell, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lantheus | 41 open or running | phase 4since Oct 3, 2023 | Nov 22, 2016 | none ahead |
| Bracco | 10 open or running | phase 4since Sep 17, 2024 | Sep 17, 2024 | none ahead |
Also a collaborator on its studies: aixial-group.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 22, 2016First study: phase 3 study in Prostatic NeoplasmsNew to LantheusLantheus · NCT02981368 · 385 enrolled · United States, Canada
- Nov 9, 2018Phase 3 study in Prostatic NeoplasmsLantheus · NCT03739684 · 208 enrolled · United States, Canada
- Oct 3, 2023Phase 4 study in Prostatic NeoplasmsLantheus · NCT06074510 · 274 enrolled · United States
- Sep 17, 2024Bracco's first study: phase 4 study in Prostatic NeoplasmsNew to BraccoBracco · NCT06604442 · 62 enrolled · United States
- May 30, 2025Phase 3 study in Carcinoma, Renal CellLantheus · NCT07084909 · United States
TargetBeta
“A urea-based radiotracer composed of the prostate specific membrane antigen (PSMA) targeting agent DCFPyL and ”NCIt, by rule
Other programs on FOLH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| flotufolastat F 18rule | Bracco | phase 4 | 7 |
| abefolastat tesaroxetan CU-64rule | clarity-pharmaceuticals-ltd | phase 3 | 5 |
| gallium 68 PSMA-11rule | Novartis | phase 3 | 4 |
| Lutetium Lu 177 Ludotadipeprule | futurechem | phase 3 | 3 |
| Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 | Johnson & Johnson | phase 3 | 2 |
| Lutetium Lu 177 NYM032rule | Norroy Bioscience | phase 3 | 2 |
| actinium AC-225 vipivotide tetraxetan | Novartis | phase 3 | 2 |
| HRS-4357 | Jiangsu HengRui Medicine | phase 3 | 2 |
| zadavotide guraxetan | AstraZeneca | phase 2 | 4 |
| AB-001rule | frontier-biotechnologies-inc | phase 2 | 3 |
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 2 |
| SHR-4394 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07084909Carcinoma, Renal Cell · United States | 3 | Withdrawn | Lantheus | Sep 2027 | 0 |
| NCT06604442Prostatic Neoplasms · United States | 4 | Completed | Bracco | Aug 29, 2025 | 62 |
| NCT06074510Prostatic Neoplasms · United States | 4 | Active, not recruiting | Lantheus | Sep 2026 | 274 |
| NCT03739684Prostatic Neoplasms · United States, Canada | 3 | Completed | Lantheus | Aug 29, 2019 | 208 |
| NCT02981368Prostatic Neoplasms · United States, Canada | 3 | Completed | Lantheus | Jul 2018 | 385 |
How it is read
Names in the registry
- “piflufolastat (18F)”, 1 entry
- “piflufolastat F 18”, 1 entry
- “Piflufolastat F 18 Intravenous Solution [PYLARIFY]”, 1 entry
- “18F-DCFPyL Injection”, 1 entry
- “18F-DCFPyL”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 4 studies
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.